Zonegran and Afinitor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zonegran (zonisamide) and Afinitor (everolimus). Common drug interactions include dysmenorrhoea among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Zonegran and Afinitor. It is created by eHealthMe based on reports of 69 people who take the same drugs from the FDA, and is updated regularly.

What is Zonegran?

Zonegran has active ingredients of zonisamide. It is often used in epilepsy. eHealthMe is studying from 6,211 Zonegran users. Check the latest studies of Zonegran.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 41,680 Afinitor users. Check the latest studies of Afinitor.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 28, 2026

69 people who take Zonegran and Afinitor together, and have interactions are studied.

Zonegran and Afinitor drug interactions.

What are the common drug interactions of Zonegran and Afinitor, by gender? *:

female:

  1. Dysmenorrhoea (painful menstruation)
  2. Menstruation irregular
  3. Mouth ulceration (mouth ulcers)
  4. Neoplasm progression (growth of tumour)
  5. Aphthous ulcer (mouth ulcer)
  6. Headache (pain in head)
  7. Therapeutic response decreased (less preventive response)
  8. Somnolence (a state of near-sleep, a strong desire for sleep)
  9. Abnormal behaviour
  10. Acne (skin problems that cause pimples)

male:

  1. Cough
  2. Diarrhoea
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Blood triglycerides increased
  5. Ocular neoplasm (eye tumour)
  6. Complex partial seizures (epileptic seizure)
  7. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  8. Loss of consciousness
  9. Rash
  10. Herpes zoster

What are the common drug interactions of Zonegran and Afinitor, by age (0-1 to 60+)? *:

0-1:

  1. Coma (state of unconsciousness lasting more than six hours)
  2. Complex partial seizures (epileptic seizure)
  3. Cough
  4. Diarrhoea
  5. Ear infection
  6. Electrolyte imbalance
  7. Infantile spasms
  8. Rhinorrhoea (watery mucus discharge from the nose)
  9. Somnolence (a state of near-sleep, a strong desire for sleep)
  10. Vomiting

2-9:

  1. Drug level increased
  2. Viral infection
  3. Cough
  4. Decreased appetite
  5. Diarrhoea
  6. Eye disorder
  7. Infantile spasms
  8. Influenza
  9. Influenza like illness
  10. Irritability

10-19:

  1. Blood cholesterol increased
  2. Neoplasm progression (growth of tumour)
  3. Abnormal behaviour
  4. Pyrexia (fever)
  5. Staphylococcal infection (an infection with staphylococcus bacteria)
  6. Blood triglycerides increased
  7. Vomiting
  8. Blood pressure increased
  9. Drug level increased
  10. Astrocytoma, low grade (low grade tumour of the brain that originate in a particular kind of glial-cells)

20-29:

  1. Oliguria (not enough urine)
  2. Oropharyngeal pain
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  4. Eye infection
  5. Fall
  6. Foot fracture
  7. Oral pain
  8. Peripheral swelling
  9. Stomatitis (inflammation of mucous membrane of mouth)
  10. Drug level below therapeutic

30-39:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Herpes zoster
  3. Rash
  4. Drug level decreased
  5. Apnoeic attack
  6. Joint injury
  7. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  8. Angiofibroma (small, reddish brown or even flesh-coloured, smooth, shiny, 0.1- to 0.3 cm papules present over the sides of the nose and the medial portions of the cheeks)
  9. Decreased appetite
  10. Diarrhoea

40-49:

n/a

50-59:

  1. Blood cholesterol increased
  2. Chills (felling of cold)
  3. Cough
  4. Dysmenorrhoea (painful menstruation)
  5. Haematuria (presence of blood in urine)
  6. Menorrhagia (an abnormally heavy bleeding and prolonged menstrual period at regular intervals)
  7. Menstrual disorder (disease of menstrual cycle)
  8. Menstruation irregular
  9. Nasopharyngitis (inflammation of the nasopharynx)
  10. Neoplasm progression (growth of tumour)

60+:

  1. Blood triglycerides increased
  2. Coma (state of unconsciousness lasting more than six hours)
  3. Somnolence (a state of near-sleep, a strong desire for sleep)
  4. Vomiting
  5. Complex partial seizures (epileptic seizure)
  6. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  7. Heart rate increased
  8. Infection
  9. International normalised ratio increased
  10. Loss of consciousness

What are the existing conditions these people have? *

  1. Angiomyolipoma (most common benign tumour of the kidney): 21 people, 30.43%
  2. Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 16 people, 23.19%
  3. Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 11 people, 15.94%
  4. Brain Neoplasm Benign (non-cancerous tumour of brain): 8 people, 11.59%
  5. Seizures (abnormal excessive or synchronous neuronal activity in the brain): 6 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Zonegran and Afinitor?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Zonegran and Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zonegran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Afinitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zonegran and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Afinitor and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on zonisamide and everolimus (the active ingredients of Zonegran and Afinitor, respectively), and Zonegran and Afinitor (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: